ClearPoint Neuro (CLPT)

Overall impact
C (51)

Commentary

ClearPoint Neuro is an average overall performer. With a 'C' rating of 51.0 for overall impact (43rd percentile compared to all companies), ClearPoint Neuro ranks 529th out of 585 industry peers, behind Grifols, Biogen, Ionis Pharmaceuticals and 525 others, and ahead of Jazz Pharmaceuticals, Citius Pharmaceuticals, Verona Pharma and 53 others. On top material causes for ClearPoint Neuro's industry (Pharmaceuticals & Biotech), ClearPoint Neuro performs well in Child and Maternal Health (80.4 score) and Disease Eradication (96.4) and performs poorly in Humane Treatment of Animals (2.0 score), Reduced Green House Gas Emissions (21.7), Decent, Safe Work Opportunities (24.1) and 3 other causes where it received a 'D' or 'F' score.
Impact
Cause CLPT
Peer rank
Overall impact

Log in to view this information

Impact trend

Change in rating for overall impact

Log in to view this information

Company
Founded
1998
Employees
115
Sector
Health Care
Industry
Biotechnology
Sub-industry
Biotechnology
SASB industry
Biotechnology & Pharmaceuticals
Headquarters
Ca, United States
Share classes
CLPT
Description
ClearPoint Neuro, Inc. operates as a medical device company primarily in the United States. It develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under magnetic resonance imaging guided interventions. The company offers ClearPoint system, an integrated system for the insertion of deep brain stimulation electrodes, biopsy needles, and laser catheters, as well as the infusion of pharmaceuticals into the brain. It has license and collaboration agreement with Clinical Laserthermia Systems AB; license and research agreement with Koninklijke Philips N.V.; UCB Biopharma SRL; NE Scientific, LLC; and University of California, San Francisco, and Johns Hopkins University. The company was formerly known as MRI Interventions, Inc. and changed its name to ClearPoint Neuro, Inc. in February 2020. ClearPoint Neuro, Inc. was incorporated in 1998 and is headquartered in Solana Beach, California.
Material causes
Ethos considers the following causes material for ClearPoint Neuro, based on its industry sub-industry Biotechnology. Learn more about material causes in our methodology overview.

This information is subject to Ethos' Terms and Conditions, which you can find here.

This information may not be used for corporate financing purposes (including, without limitation, ESG-linked loans, credit facilities, securities or structured products), as a basis for any financial instruments or products (including, without limitation, passively managed funds and index-linked derivative securities) or other products or services, to verify or correct data in any other compilation of data or index, to create any derivative works, nor to create any other data or index (custom or otherwise), without Ethos' prior written permission.

By browsing this site you agree to our use of cookies. Read more.
We use cookies on this site to enhance your user experience. By continuing to browse the site, you are agreeing to our use of cookies. Give me more info.